
Browsing restrictions can be lifted for a fee.
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding cerebral vascular surgery; and tissue repair and regeneration products for the treatment of early osteoarthritis. Taiwan Biomaterial Co., Ltd. Was founded in 2010 and is based in Zhubei, Taiwan.
6649
台生材
-1.94%
(-0.02)
The most recent financial report for 台生材 (6649) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6649's short-term business performance and financial health. For the latest updates on 6649's earnings releases, visit this page regularly.
According to historical valuation range analysis, 台生材 (6649)'s current price-to-earnings (P/E) ratio is 50.43, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 台生材 (6649) reported an Operating Profit of 25.56M with an Operating Margin of 35.12% this period, representing a growth of 1,716.64% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 台生材 (6649) announced revenue of 72.78M, with a Year-Over-Year growth rate of 164.73%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 台生材 (6649) held Total Cash and Cash Equivalents of 256M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 台生材 (6649) achieved the “three margins increasing” benchmark, with a gross margin of 60.46%%, operating margin of 35.12%%, and net margin of 39.36%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6649's profit trajectory and future growth potential.
According to the past four quarterly reports, 台生材 (6649)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.68. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
台生材 (6649)'s Free Cash Flow (FCF) for the period is 2.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 530.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.